Johnson & Johnson Cash and Restricted Cash
Johnson & Johnson (JNJ) had Cash and Restricted Cash of $20.42 billion as of 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-23
- 2026-06-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.42B.
- 2026-03-29: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21.69B.
- 2025-12-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.71B.
- 2025-09-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.23B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-28 | $20.42B 10-Q · filed 2026-07-23 |
| 2026-03-29 | $21.69B 10-Q · filed 2026-04-22 |
| 2025-12-28 | $19.71B 10-Q · filed 2026-07-23 |
| 2025-09-28 | $18.23B 10-Q · filed 2025-10-22 |
| 2025-06-29 | $18.58B 10-Q · filed 2026-07-23 |
| 2025-03-30 | $38.47B 10-Q · filed 2026-04-22 |
| 2024-12-29 | $24.11B 10-Q · filed 2026-07-23 |
| 2024-09-29 | $19.98B 10-Q · filed 2025-10-22 |
| 2024-06-30 | $24.88B 10-Q · filed 2025-07-24 |
| 2024-03-31 | $25.47B 10-Q · filed 2025-04-23 |
| 2023-12-31 | $21.86B 10-K · filed 2026-02-11 |
| 2023-10-01 | $19.73B 10-Q · filed 2024-10-23 |
| 2023-07-02 | $21.18B 10-Q · filed 2024-07-25 |
| 2023-04-02 | $26.86B 10-Q · filed 2024-05-01 |
| 2023-01-01 | $14.13B 10-K · filed 2026-02-11 |
| 2022-10-02 | $11.36B 10-Q · filed 2023-10-27 |
| 2022-07-03 | $10.98B 10-Q · filed 2023-07-31 |
| 2022-04-03 | $10.46B 10-Q · filed 2023-04-28 |
| 2022-01-02 | $14.49B 10-K · filed 2025-02-13 |
| 2021-10-03 | $17.60B 10-Q · filed 2022-10-27 |
| 2021-07-04 | $14.33B 10-Q · filed 2022-07-29 |
| 2021-04-04 | $12.67B 10-Q · filed 2022-04-29 |
| 2021-01-03 | $13.98B 10-K · filed 2024-02-16 |
| 2020-09-27 | $18.96B 10-Q · filed 2021-10-29 |
| 2020-06-28 | $11.17B 10-Q · filed 2021-07-29 |
| 2020-03-29 | $15.53B 10-Q · filed 2021-04-30 |
| 2019-12-29 | $17.30B 10-K · filed 2023-02-16 |
| 2019-09-29 | $16.25B 10-Q · filed 2020-10-23 |
| 2019-06-30 | $14.38B 10-Q · filed 2020-07-24 |
| 2019-03-31 | $14.73B 10-Q · filed 2020-04-29 |
| 2018-12-30 | $18.11B 10-K · filed 2022-02-17 |
| 2018-09-30 | $16.06B 10-Q · filed 2019-10-28 |
| 2017-12-31 | $17.82B 10-K · filed 2021-02-22 |
| 2017-01-01 | $18.97B 10-K · filed 2020-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |